In:
Scientific Reports, Springer Science and Business Media LLC, Vol. 8, No. 1 ( 2018-02-07)
Abstract:
CD8 + T-cell expansions are the primary manifestation of T-cell large granular lymphocytic leukemia (T-LGLL), which is frequently accompanied by neutropenia and rheumatoid arthritis, and also occur as a secondary phenomenon in leukemia patients treated with dasatinib, notably in association with various drug-induced side-effects. However, the mechanisms that underlie the genesis and maintenance of expanded CD8 + T-cell receptor (TCR)-Vβ + populations in these patient groups have yet to be fully defined. In this study, we performed a comprehensive phenotypic and clonotypic assessment of expanded (TCR-Vβ + ) and residual (TCR-Vβ − ) CD8 + T-cell populations in T-LGLL and dasatinib-treated chronic myelogenous leukemia (CML) patients. The dominant CD8 + TCR-Vβ + expansions in T-LGLL patients were largely monoclonal and highly differentiated, whereas the dominant CD8 + TCR-Vβ + expansions in dasatinib-treated CML patients were oligoclonal or polyclonal, and displayed a broad range of memory phenotypes. These contrasting features suggest divergent roles for antigenic drive in the immunopathogenesis of primary versus dasatinib-associated CD8 + TCR-Vβ + expansions.
Type of Medium:
Online Resource
ISSN:
2045-2322
DOI:
10.1038/s41598-017-18062-x
Language:
English
Publisher:
Springer Science and Business Media LLC
Publication Date:
2018
detail.hit.zdb_id:
2615211-3
